Plain-English translation of NCT06182839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called canagliflozin can help protect your heart and slow the progression of advanced kidney disease. Researchers will compare people who take this medication daily to those who receive a placebo (a pill with no active ingredient). The study will use special heart imaging scans to see if the medication makes a difference.
People with advanced kidney disease are at high risk for heart problems and continued kidney damage. Researchers want to see whether this medication, which works on the kidneys and heart in a specific way, can help protect these organs and improve outcomes for patients with severe kidney disease.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either canagliflozin or a placebo tablet once daily for one year. During this time, you'll have regular visits where doctors will monitor your symptoms, check for any side effects, and perform heart imaging scans using MRI. If you're not yet on dialysis, your treatment will continue if you later start dialysis or receive a kidney transplant. All your other medications and dialysis treatments will be managed as usual by your regular doctors.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada